LEUVEN, Belgium, April 13, 2012 /PRNewswire/ --
ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces that it has received a transparency declaration from OppenheimerFunds Inc. in accordance with the Belgian Law of 2 May 2007 concerning disclosure of major holdings in issuers whose shares are admitted to trading on a Belgian regulated market.
ThromboGenics NV has received a transparency notification from OppenheimerFunds Inc., having its registered office at S.Tucson Way 6803, Centennial, Colorado US, indicating that, following the acquisition of shares, its participation in the company exceeds the 3% threshold. Following the private placement of 29 March 2012, ThromboGenics has now 35.691.432 shares outstanding. As a consequence of this capital increase 2 shareholders have passed a threshold of respectively 10% (L.T.Clay) and 5% (Baker Brothers) as they did not participate in the recent capital increase.
As per 13 April 2012, based on the transparency notifications received, ThromboGenics NV has been informed of the following major shareholdings:
Shareholder Number of shares % of outstanding shares Landon T Clay 2.576.448 7,21 Biggar Ltd 2.012.105 5,64 Baker Brothers 1.619.488 4,54 OppenheimerFunds Inc. 1.236.688 3,46 Clay Mathematics 1.099.247 3,07
ThromboGenics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The company's lead product, ocriplasmin, has successfully completed two Phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (VMA). The MAA for ocriplasmin has been accepted for review in Europe and the BLA will be re-submitted in the U.S. by April 2012. Ocriplasmin is in Phase II clinical development for additional vitreoretinal conditions.
In March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of ocriplasmin outside the United States. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments, plus an attractive level of royalties on Alcon's net sales of ocriplasmin. ThromboGenics and Alcon intend to share the costs equally of developing ocriplasmin for a number of new vireoretinal indications.
ThromboGenics is also developing two novel antibody therapeutics in collaboration with BioInvent International. These are TB-402 (anti-Factor VIII), a long-acting anticoagulant in Phase II, and TB-403 (anti-PlGF), in Phase Ib/II for cancer which has been partnered with Roche.
ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at http://www.thrombogenics.com.
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. These forward-looking statements may be identified by references to strategy, plans, objectives, goals, future events or intentions. Forward-looking statements may and often do differ materially from actual results. The company therefore cannot provide any assurance that such forward-looking statements will materialize. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the company's annual report.
For further information please contact:
ThromboGenics NV Tel: +32-16-75-13-10 Chris Buyse, CFO firstname.lastname@example.org Citigate Dewe Rogerson Tel: +44-(0)-207-638-9571 David Dible/ Nina Enegren/ Sita Shah email@example.com
SOURCE ThromboGenics NV